Schizophrenia.com

Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

3 Likes

This is what I’m hoping for…

1 Like

Thanks for the article. I am hoping some of these get approved.
Unfortunately, my insurance will categorize any new approved in such a way that I would have to pay half the cost or $500-650 a month.
My income is too high to qualify for patient assistance.

1 Like

They left off the most promising one, Karxt.

3 Likes

I believe they have discontinued research on that one after a phase 3 failure. Although you never know, sometimes the phase 3 failures get purchased by other companies that try to develop biomarkers for who they can help - once something makes it to phase 3 it does seem likely that it helps at least some people.

I haven’t seen anything on F17464 in years, I stopped following it. What I did read about it looked good though.

2 Likes